Innovative drug concept stocks continued to strengthen, Warner Pharmaceuticals rose more than 10% to a record high, and many stocks of Celly Medical, Lianhuan Pharmaceutical, Qianyuan Pharmaceutical, and Hisun Pharmaceutical hit the daily limit. Goldman Sachs pointed out that the overall market value of Chinese biotech companies is still only 14%-15% of their US counterparts, while their contribution to global innovation is close to 33%. This means that China's innovative drug sector is still in the "value depression" stage, and the global capital revaluation has just begun.